Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Simon Marchant, a DPhil student at the Paediatric Neuroimaging Group [https://neuroimaging.paediatrics.ox.ac.uk/], has been awarded the Postgraduate Research Award by the Institute of Engineering and Technology. The award, worth £2,500, was given in recognition of his outstanding engineering research in the field of paediatric neuroimaging.

Simon, who is also a Chartered Engineer and Clinical Scientist, applies machine learning techniques to neurophysiological measurements from infant brains, to develop new ways of analysing the data. This award will enable him to expand his experience and collaborations and apply his research to solve real clinical problems. 

His work has previously been recognised by the Alan Turing Institute, and the National Institute of Health Research. The IET Awards, which are designed to promote excellence in engineering research, provide support for high-quality engineers and encourage them to develop successful academic research careers.  

Professor Bob Cryan CBE, IET President said: “Supporting personal and professional development for todays and tomorrow’s engineers, and research into new technology are things we are really passionate about. Our global IET Postgraduate Research Awards are given on a competitive basis for excellence, and the related financial support forms part of the IET’s annual investment in the next generation of engineers.” 

Similar stories

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.